-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] In the morning news on June 7, the pharmaceutical sector was active, and many sub-segments such as traditional Chinese medicine and CRO ro.
Among them, the CRO concept stock Baicheng Pharmaceutical rose by more than 15%, and Heyuan Bio, Medicilon Up more than 5%; among Chinese medicine concept stocks, Xintian Pharmaceutical .
, L.
rose by the daily limit, and Jiangzhong Pharmaceutical .
, L.
and Dali Pharmaceutical .
, L.
rose close to 1
As of 10:44, the price of Baicheng Pharmaceutical's stock price was 755 yuan, the turnover was 191 million, the turnover rate was 183%, and the price-earnings (TTM) was 61On the news, Baicheng Pharmaceutical announced on the evening of June 6 that it planned to grant about 5833 million restricted shares to 197 incentive objects, accounting for about 39% of the company's total share capital of about 108 million shares on the date of the announcement of the draft incentive pl.
According to the data, Baicheng Pharmaceutical is a comprehensive pharmaceutical R&D enterprise with technology development as the co.
Its business covers the whole chain of drug R&D and production, including drug discovery, pharmaceutical research, clinical trials, customized R&D and production, and registration applicati.
The company mainly provides various pharmaceutical companies and pharmaceutical R&D investment companies: pharmaceutical technology entrusted R&D services (CRO business), R&D technology achievement transformation services, and customized R&D production services (CDM.
In recent years, Baicheng Pharmaceutical’s performance has grown steadi.
In 2021, its operating income will be about 374 million yuan, a year-on-year increase of 861%; the net profit attributable to shareholders of listed companies is about 111 million yuan, a year-on-year increase of 952%; basic earnings per share are 37 yu.
, a year-on-year increase of 99
On the same day, Xintian Pharmaceutical hit the daily limit, with a quotation of 145 yuan, a turnover of 137 million, a turnover rate of 47%, and a price-earnings (TTM) of 27The stock has risen by the limit 15 times in the past ye.
In the news, Shanghai has cancelled the whitelist system for enterprises to resume work and production since June 1, and will support manufacturing enterprises including biopharmaceuticals and other manufacturing companies to lead the chain, realize the coordinated resumption of work by upstream and downstream enterprises in the industrial chain and supply chain, and steadily increase the production capacity of enterpris.
ra.
Kaiyuan Securities believes that medical care is a rigid demand, and it is expected that the demand for university scientific research, pharmaceutical research and development, and medical services delayed by the epidemic will recover flexibly in the future, and the operating performance of related targets, including Xintian Pharmaceutical, is expected to grow rapid.
According to the data, the main business of Xintian Pharmaceutical is the research and development, production and sales of Chinese patent medicin.
Yixue Oral Liquid, Xinlikang Capsules, Relinqing Tablets, Xinlikang Granules, Longzhang Mouth Liquid, Cold Relieving Cough Capsules, Relinqing Syrup, Xiaoyu Jiangzhi Capsul.
The 2021 annual report shows that the company achieved a total operating income of 970 million yuan, a year-on-year increase of 215%; net profit attributable to the parent was 101 million yuan, a year-on-year increase of 37
In addition, during the reporting period, the company's basic earnings per share was 6193 yuan, and the weighted average return on equity was 17
In recent years, the state has continuously introduced heavy support policies to promote the development of the traditional Chinese medicine industry and encourage the inheritance and innovation of traditional Chinese medici.
The company now has 3 new traditional Chinese medicine products, namely Longcen Pengqiangshu Granules, Ku'e Jieyin Gel, and Shuyutong Granules, all of which have completed Phase III clinical trials, and 445 varieties of traditional Chinese medicine formula granul.
Medical research, and actively carry out secondary developme.
The company has increased its capital in Huilun Biotechnology four times and entered the field of small molecule chemical drugs, with a shareholding ratio of 188% by the end of 202Huilun Bio has successively obtained more than ten drug registration approvals such as "Sivelestat Sodium for Injection", and has been listed and sold on a large sca.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Click to enter the exhibition page
Among them, the CRO concept stock Baicheng Pharmaceutical rose by more than 15%, and Heyuan Bio, Medicilon Up more than 5%; among Chinese medicine concept stocks, Xintian Pharmaceutical .
, L.
rose by the daily limit, and Jiangzhong Pharmaceutical .
, L.
and Dali Pharmaceutical .
, L.
rose close to 1
As of 10:44, the price of Baicheng Pharmaceutical's stock price was 755 yuan, the turnover was 191 million, the turnover rate was 183%, and the price-earnings (TTM) was 61On the news, Baicheng Pharmaceutical announced on the evening of June 6 that it planned to grant about 5833 million restricted shares to 197 incentive objects, accounting for about 39% of the company's total share capital of about 108 million shares on the date of the announcement of the draft incentive pl.
According to the data, Baicheng Pharmaceutical is a comprehensive pharmaceutical R&D enterprise with technology development as the co.
Its business covers the whole chain of drug R&D and production, including drug discovery, pharmaceutical research, clinical trials, customized R&D and production, and registration applicati.
The company mainly provides various pharmaceutical companies and pharmaceutical R&D investment companies: pharmaceutical technology entrusted R&D services (CRO business), R&D technology achievement transformation services, and customized R&D production services (CDM.
In recent years, Baicheng Pharmaceutical’s performance has grown steadi.
In 2021, its operating income will be about 374 million yuan, a year-on-year increase of 861%; the net profit attributable to shareholders of listed companies is about 111 million yuan, a year-on-year increase of 952%; basic earnings per share are 37 yu.
, a year-on-year increase of 99
On the same day, Xintian Pharmaceutical hit the daily limit, with a quotation of 145 yuan, a turnover of 137 million, a turnover rate of 47%, and a price-earnings (TTM) of 27The stock has risen by the limit 15 times in the past ye.
In the news, Shanghai has cancelled the whitelist system for enterprises to resume work and production since June 1, and will support manufacturing enterprises including biopharmaceuticals and other manufacturing companies to lead the chain, realize the coordinated resumption of work by upstream and downstream enterprises in the industrial chain and supply chain, and steadily increase the production capacity of enterpris.
ra.
Kaiyuan Securities believes that medical care is a rigid demand, and it is expected that the demand for university scientific research, pharmaceutical research and development, and medical services delayed by the epidemic will recover flexibly in the future, and the operating performance of related targets, including Xintian Pharmaceutical, is expected to grow rapid.
According to the data, the main business of Xintian Pharmaceutical is the research and development, production and sales of Chinese patent medicin.
Yixue Oral Liquid, Xinlikang Capsules, Relinqing Tablets, Xinlikang Granules, Longzhang Mouth Liquid, Cold Relieving Cough Capsules, Relinqing Syrup, Xiaoyu Jiangzhi Capsul.
The 2021 annual report shows that the company achieved a total operating income of 970 million yuan, a year-on-year increase of 215%; net profit attributable to the parent was 101 million yuan, a year-on-year increase of 37
In addition, during the reporting period, the company's basic earnings per share was 6193 yuan, and the weighted average return on equity was 17
In recent years, the state has continuously introduced heavy support policies to promote the development of the traditional Chinese medicine industry and encourage the inheritance and innovation of traditional Chinese medici.
The company now has 3 new traditional Chinese medicine products, namely Longcen Pengqiangshu Granules, Ku'e Jieyin Gel, and Shuyutong Granules, all of which have completed Phase III clinical trials, and 445 varieties of traditional Chinese medicine formula granul.
Medical research, and actively carry out secondary developme.
The company has increased its capital in Huilun Biotechnology four times and entered the field of small molecule chemical drugs, with a shareholding ratio of 188% by the end of 202Huilun Bio has successively obtained more than ten drug registration approvals such as "Sivelestat Sodium for Injection", and has been listed and sold on a large sca.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Click to enter the exhibition page
